Hem/Onc Today (Healio)Results of KEYNOTE-716 Trial May ‘Level the Playing Field Against Melanoma’

The results, presented during the virtual ESMO Congress 2021, will substantially change the population of patients with melanoma who undergo treatment in the adjuvant setting, according to Jason J. Luke, MD: “Patients with stage IIB/C melanoma have similar rates of recurrence and melanoma specific survival to those with stage IIIA/B disease. Despite this, adjuvant anti-PD-1 […]

MedPage TodayAdjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma

Dr. Kenneth Grossmann commented after presenting the results at the ASCO Annual Meeting in June: “The overall survival impact of pembrolizumab was likely influenced by effective post-relapse treatment, with standard-of-care patients receiving PD-1 blockade.” Dr. Grossmann then concluded that “single-agent anti-PD-1 antibody treatment should be a standard-of-care option for adjuvant treatment of high-risk resected melanoma,” […]

Cancer Therapy AdvisorLEAP-004: Durable Responses in Advanced Melanoma Achieved With Lenvatinib Plus Pembrolizumab

Lead author of the study, Dr. Ana Maria Arance, who presented the results over the summer at the ASCO Annual Meeting, commented: “With additional follow-up, lenvatinib plus pembrolizumab continues to show clinically meaningful, durable responses in patients with advanced melanoma with confirmed progression on a PD-1 or PD-L1 inhibitor given alone or in combination. These […]

Everyday HealthAdjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma

Presented at the virtual American Society of Clinical Oncology (ASCO) annual meeting, the findings from the S1404 clinical trial demonstrated that, although the PD-1 inhibitor pembrolizumab (Keytruda) came up short in both the intent-to-treat (ITT) population and PD-L1-positive subgroup, relapse-free survival (RFS) was significantly improved compared with those who received either ipilimumab (Yervoy) or high-dose […]

Dana-Farber Cancer InstituteImmunotherapy Combination Shows Benefit for Patients w. Advanced Melanoma, Phase 3 Trial Shows

The results of the trial, known as the RELATIVITY-047 study, were presented at the virtual ASCO Annual Meeting that took place June 4-8, 2021. The Dana-Farber Cancer Institute Investigators who co-led the study were thrilled to present that, despite PD-1 blocker nivolumab revolutionizing the treatment of patients with advanced melanoma, this fixed-dose combination of nivolumab […]

M35 Cancer-Fighting Foods That Have Researchers’ Attention

According to the American Institute for Cancer Research, a diet filled with a variety of vegetables, fruits, whole grains, beans, and other plant foods helps lower risk for many cancers, thanks to their bioactive compounds. Things like bergamottin. Isothiocyanates. Polyphenols. Continue reading to discover five foods that have the potential to fight cancer, including pancreatic, […]